Reasons why patients infected with chronic hepatitis C virus choose to defer treatment: Do they alter their decision with time?

Digestive Diseases and Sciences

Volumn 52, Issue 5, 2007, Pages 1168-1176

  Khokhar, Omar S ^a   Lewis, James H ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Chronic hepatitis C; Deferred treatment; Patient satisfaction

Indexed keywords

ALANINE AMINOTRANSFERASE; PEGINTERFERON; RIBAVIRIN;

ADULT; AFRICAN AMERICAN; AGE DISTRIBUTION; AGED; ARTICLE; COMORBIDITY; CONSULTATION; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DISEASE DURATION; DRUG EFFICACY; ENZYME BLOOD LEVEL; EXPECTATION; FEMALE; FOLLOW UP; GENDER; GENOTYPE; HEALTH INSURANCE; HEALTH PROGRAM; HEALTH SURVEY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; INFORMED CONSENT; INTRAVENOUS DRUG ABUSE; LIVER BIOPSY; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MEDICAL RECORD REVIEW; PATIENT DECISION MAKING; PATIENT SATISFACTION; PRIORITY JOURNAL; QUESTIONNAIRE; RACE; RETROSPECTIVE STUDY; SOCIAL ASPECT; SOCIAL PSYCHOLOGY; SOCIAL SUPPORT; TREATMENT CONTRAINDICATION; TREATMENT REFUSAL; VIRUS LOAD;

ADULT; AGE FACTORS; AGED; ANTIVIRAL AGENTS; CHOICE BEHAVIOR; FEMALE; FOLLOW-UP STUDIES; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; MALE; MIDDLE AGED; PATIENT SATISFACTION; QUESTIONNAIRES; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SEX FACTORS; SOCIOECONOMIC FACTORS; TIME FACTORS; TREATMENT REFUSAL;

EID: 34247200049     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-006-9579-1     Document Type: Article

References (58)

1. Fried MW, Hadziyannis SJ (2004) Treatment of chronic hepatitis C infection with peginterferons plus ribavirin. Semin Liver Dis 24(Suppl 2):47-54
2. Ferenci P (2004) Predictors of response to therapy for chronic hepatitis C. Semin Liver Dis 24(Suppl 2):25-31
3. Pawlotsky JM (2006) Therapy of hepatitis C: From empiricism to eradication. Hepatology 43(S1):S207-S220
4. Anonymous (2002) National Institutes of Health Consensus Development Conference Statement: management of hepatitis C. Hepatology 36(Suppl 1):S3-S20
5. Strader DB, Wright T, Thomas DL, Seeff LB (2004) Diagnosis, management, and treatment of hepatitis C. Hepatology 1147-1171
6. Wang P, Yi Q, Scully L (2003) Indications for interferon/ribavirin therapy in hepatitis C patients: findings from a survey of Canadian hepatologists. Can J Gastroenterol 17:183-186
7. Ward RP, Kugelmas M, Libsch KD (2004) Management of hepatitis C: evaluating suitability for drug therapy. Am Fam Physician 69:1429-1436
8. Herrine SK (2002) Approach to the patient with chronic hepatitis C virus infection. Ann Intern Med 136:747-757
9. Reddy KR (2004) Hepatitis C with normal liver enzymes: to treat or not to treat. Con: most patients should not be treated. Am J Gastroenterol 99:973-975
10. Koff JM, Younossi Z (2004) Hepatitis C with normal liver enzymes: to treat or not to treat. Pro: most patients should be treated. Am J Gastroenterol 99: 972-973
11. Thomas DL, Seeff LB (2005) Natural history of hepatitis C. Clin Liver Dis 9:383-398
12. Poynard T, Ratziu V, Charlotte F, et al. (2001) Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 34:730-739
13. Ryder SD on behalf of the Trent Hepatitis C Study Group (2004) Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut 53:451-455
14. Wong JB, Koff RS for the International Hepatitis Interventional Therapy Group (2000) Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. A cost-effectiveness analysis. Ann Intern Med 133:665-675
15. Afdhal NH (2004) The natural history of hepatitis C. Semin Liver Dis 24(Suppl 2):3-8
16. Bini EJ, Brau N, Currie S, et al. (2005) Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection. Am J Gastroenterol 100:1772-1179
17. Cheung RC, Currie S, Shen H, et al. (2005) Chronic hepatitis C in Latinos: natural history, treatment eligibility, acceptance, and outcomes. Am J Gastroenterol 100:2186-2193
18. Falck-Ytter Y, Kale H, Mullen KD, et al. (2002) Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 136:288-292
19. Cawthorne CH, Rudat KR, Burton MS, et al. (2002) Limited success of HCV antiviral therapy in United States veterans. Am J Gastroenterol 97:149-155
20. De Bie J, Robaeys G, Buntinx F (2005) Hepatitis C, interferon alpha and psychiatric co-morbidity in intravenous drug users (IVDU): guidelines for clinical practice. Acta Gastroenterol Belg 68:68-80
21. Lehman CL, Cheung RC (2002) Depression, anxiety, posttraumatic stress, and alcohol-related problems among veterans with chronic hepatitis C. Am J Gastroenterol 97:2640-2646
22. Muir AJ, Provenzale D (2002) A descriptive evaluation of eligibility for therapy among veterans with chronic hepatitis C virus infection. J Clin Gastroenterol 34:268-271
23. Rowan PJ, Tabasi S, Abdul-Latif M, et al. (2004) Psychosocial factors are themost common contraindications for antiviral therapy at initial evaluation in veterans with chronic hepatitis C. J Clin Gastroenterol 38:530-534
24. Butt AA, Wagener M, Shakil AO, et al. (2005) Reasons for non-treatment in hepatitis C in veterans in care. J Viral Hepatol 12:81-85
25. Tavakoli-Tabasi S, Rowan P, Abdul-Latif M, et al. (2005) Utility of a depression score to predict candidacy for hepatitis C virus therapy in veterans: a prospective longitudinal study. Aliment Pharmacol Ther 21:235-242
26. Nguyen HA, Miller AI, Dieperink E, et al. (2002) Spectrum of disease in U.S. veteran patients with hepatitis C. Am J Gastroenterol 97:1813-1820
27. Fireman M, Indest DW, Blackwell A, et al. (2005) Addressing tri-morbidity (hepatitis C, psychiatric disorders, and substance use): the importance of routine mental health screening as a component of a comanagement model of care. Clin Infect Dis 40(Suppl 5):S286-S291
28. Schaefer M, Schmidt F, Folwaczny C, et al. (2003) Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 37:443-451
29. Allen SA, Spaulding AC, Osei AM, et al. (2006) Treatment of hepatitis C in a state correctional facility. Ann Intern Med 138:187-190
30. Geppert CMA, Arora S (2005) Ethical issues in the treatment of hepatitis C. Clin Gastroenterol Hepatol 3:937-944
31. Srivastava S, Bertagnolli M, Lewis JH (2005) Sustained virological response rate to pegylated interferon plus ribavirin for chronic hepatitis C in African Americans: results in treatment-naïve patients in a university liver clinic. J Natl Med Assoc 97:1703-1707
32. Gallegos-Orozco JF, Loaeza-del Castillo A, Fuentes AP, et al. (2005) Early hepatitis C virus changes and sustained response in patients with chronic hepatitis C treated with peginterferon alpha-2b and ribavirin. Liver Int 25:91-95
33. Carlsson T, Reichard O, Norkrans G, et al. (2005) Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon-alpha 2a and ribavirin according to virological response. J Viral Hepatol 12:473-480
34. Knodell RG, Ishak KG, Black WC, et al. (1981) Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1:431-435
35. Ishak KG (2000) Pathologic features of chronic hepatitis: a review and update. Am J Clin Pathol 113:40-55
36. Fried MW (2002) Side effects of therapy of hepatitis C and their management. Hepatology 36(Suppl 1):S237-S244
37. Piton A, Poynard T, Imbert-Bismut F, et al. (1998) Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. MULTIVIRC Group. Hepatology 27:1213-1219
38. Elinav E, Ben-Dov IZ, Ackerman E, et al. (2005) Correlation between serum alanine aminotransferase activity and age: an inverted U curve pattern. Am J Gastroenterol 100:2201-2204
39. Andriulli A, Persico M, Iacobellis A, et al. (2004) Treatment of patients with HCV infection with or without liver biopsy. J Viral Hepatol 11:536-542
40. Shiffman ML (2004) Hepatitis C with normal liver enzymes: to treat or not to treat. A balancing view: a decision to be shared with patients. Am J Gastroenterol 99:975-976
41. Alberti A, Benvegnu L, Boccato S, et al. (2004) Natural history of initially mild chronic hepatitis C. Dig Liver Dis 36:646-654
42. Poynard T, Imbert-Bismut F, Munteanu M (2004) Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol 3:8
43. Alter HJ, Seeff LB (2000) Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis 20:17-35
44. Poynard T, Ratziu V, Benmanov Y, et al. (2000) Fibrosis in patients with chronic hepatitis C: detection and significance. Semin Liver Dis 20:47-55
45. Hui CK, Belaye T, Montegrande K, Wright TL (2003) A comparison in the progression of liver fibrosis in chronic hepatitis C between persistently normal and elevated transaminase. J Hepatol 38:511-517
46. Reddy KR, Hoofnagle JH, Tong MJ, et al. (1999) Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group. Hepatology 30:787-793
47. Pyrsopoulos N, Jeffers L (2005) Chronic hepatitis C in African Americans. Clin Liver Dis 9:427-438
48. Muir AJ, Bornstein JD, Killenberg PG (2004) Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. Atlantic Coast Hepatitis Treatment Group. N Engl J Med 350:2265-2271
49. McHutchinson JG, Poynard T, Pianko S, et al. (2000) The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Intervention Therapy Group. Gastroenterology 119:1317-1323
50. Jensen DM, Cotler SJ, Lam H, et al. (2004) A comparison of hepatitis C treatment and outcomes at academic, private and Veterans' Affairs treatment centres. Aliment Pharmacol Ther 19:69-77
51. Bellentani S, Pozzato G, Saccoccio G, et al. (1999) Clinical course and risk factors of hepatitis C virus related liver disease in the general population: report from the Dionysos study. Gut 44:874-880
52. Seeff LB, Miller RN, Rabkin CS, et al. (2000) 45-year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med 132:105-111
53. Minola E, Prati D, Suter F (2002) Age at infection affects the long-term outcome of transfusion-associated chronic hepatitis C. Blood 99:4588-4591
54. Seeff LB, Hollinger FB, Alter HJ (2001) Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: a National Heart, Lung, and Blood Institute collaborative study. Hepatology 33:455-463
55. Dev A, Patel K, McHutchison JG (2004) New therapies for chronic hepatitis C virus infection. Curr Gastroenterol Rep 6:77-86
56. Glenn JS (2005) Novel therapies for hepatitis C virus based on lessons from virology. Clin Gastroenterol Hepatol 3(Suppl 2):S86-S88
57. Keeffe EB (2005) Chronic hepatitis C: management of treatment failures. Clin Gastroenterol Hepatol 3(Suppl 2):S102-S105
58. Grant WC, Jhaveri RR, McHutchinson JG, Schulman KA, Kauf TL (2005) Trends in health care resource use for hepatitis C virus infection in the United States. Hepatology 42:1406-1413